semaglutide gallbladder symptoms GLP-1s and Your Gallbladder: What You Need to Know Does Semaglutide Cause Gallstones? Risk

Oral GLP-1 Drug Development Trends Enter a Rapid Growth Phase Currently, there are 84 oral small-molecule GLP-1 drug candidates in development worldwide, with 52 already in clinical stages

Estimated global weight loss drug sales: 2030: $93.8 billion 2029: $77.9 billion 2028: $63.7 billion 2027: $48.6 billion 2026: $35.4 billion 2025: $24.6 billion 2024: $14.8 billion 2023: $6.3 billion Source: Bloomberg Intelligence Jon Erlichman (@JonErlichman) June 22, 2024 Novo Nordisk uses semaglutide as its proprietary GLP-1 agonist in drugs that are marketed under Ozempic and Wegovy labels, with the former geared toward type-2 diabetes and the latter marketed as a treatment for obesity

Seven additional Phase 3 trials are expected to report results through 2026

Alcohol: Clinical and Experimental Research